HSHermann Pg Schneider

Hermann Pg Schneider

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hermann Pg Schneider has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy

    by H. P. G. Schneider, A. O. Mueck, H. Kuhl

    The World Health Organization International Agency for Research and Cancer (IARC), in June 2005, has classified combination hormone contraception and menopausal therapy as carcinogenic in humans. The IARC's distinction is to identify potential carcinogens associated with nutrition, environment and pharmaceutical products. They do not produce risk–benefit analyses for any country or population. Their conclusions are highly controversial in that no proof is presented for a causal relation of estrogens with reproductive cancer, be it plausibility according to mechanisms of action or experimental evidence in the animal model. Equating natural compounds like estradiol with defined carcinogens like asbestos, tobacco smoke as well as indispensable drugs such as aspirin and tamoxifen is of no substantial clinical relevance. Thus, there are no new reasons to change current management principles with combination hormone contraception and therapy.


  • Top Cited Papers
    Open Access

    The Menopause Rating Scale (MRS) scale: A methodological review

    by Klaas Heinemann, Alexander Ruebig, Peter Potthoff, Hermann Pg Schneider, Frank Strelow, Lothar Aj Heinemann, Do Minh Thai

    Background: This paper compiles data from different sources to get a first comprehensive picture of psychometric and other methodological characteristics of the Menopause Rating Scale (MRS) scale. The scale was designed and standardized as a self-administered scale to (a) to assess symptoms/complaints of aging women under different conditions, (b) to evaluate the severity of symptoms over time, and (c) to measure changes pre- and postmenopause replacement therapy. The scale became widespread used (available in 10 languages). Method: A large multinational survey (9 countries in 4 continents) from 2001/ 2002 is the basis for in depth analyses on reliability and validity of the MRS. Additional small convenience samples were used to get first impressions about test-retest reliability. The data were centrally analyzed. Data from a postmarketing HRT study were used to estimate discriminative validity. Results: Reliability measures (consistency and test-retest stability) were found to be good across countries, although the sample size for test-retest reliability was small. Validity: The internal structure of the MRS across countries was astonishingly similar to conclude that the scale really measures the same phenomenon in symptomatic women. The sub-scores and total score correlations were high (0.7–0.9) but lower among the sub-scales (0.5–0.7). This however suggests that the subscales are not fully independent. Norm values from different populations were presented showing that a direct comparison between Europe and North America is possible, but caution recommended with comparisons of data from Latin America and Indonesia. But this will not affect intra-individual comparisons within clinical trials. The comparison with the Kupperman Index showed sufficiently good correlations, illustrating an adept criterion-oriented validity. The same is true for the comparison with the generic quality-of-life scale SF-36 where also a sufficiently close association has been shown. Conclusion: The currently available methodological evidence points towards a high quality of the MRS scale to measure and to compare HRQoL of aging women in different regions and over time, it suggests a high reliability and high validity as far as the process of construct validation could be completed yet.


  • Open Access

    The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study

    by Lothar Aj Heinemann, Thai DoMinh, Frank Strelow, Silvia Gerbsch, Jörg Schnitker, Hermann Pg Schneider

    The Menopause Rating Scale is a health-related Quality of Life scale developed in the early 1990s and step-by-step validated since then. No methodologically detailed work on the utility of the scale to assess health-related changes after treatment was published before.


  • Androgens and Antiandrogens

    by H. P. G. Schneider

    Abstract: The role of androgens in women's health has been generally neglected. Currently available assays are lacking in sensitivity and reliability at the lower ranges. Circulating androgens as prohormones for other steroids (e.g., androgens) have an ubiquitous role on diverse physiological and behavioral systems. Clinical assessment of both androgen production and androgen availability can be achieved by measurement of two or three essential values. These include either total T and sex‐hormone binding globulin (SHBG), free T and SHBG, or free T and total T. The free testosterone index (total T/SHBG) correlates well with free or bioavailable T and can be used as a substitute. DHEA‐S is the most useful measure of adrenal androgen production in women. Androgen insufficiency in women is not a specific consequence of natural menopause, but may occur secondarily to the age‐related decline in both adrenal and ovarian androgen production. Since estrogen effects are also strongly linked to mood, psychological well‐being, and sexual function in women, the diagnosis of androgen insufficiency should only be made in women who are adequately estrogenized. Before initiating a trial of androgen replacement therapy, a comprehensive clinical assessment should be performed in all cases. Approved androgen replacement therapy is not yet available in most countries for treatment of female sexual dysfunction. This would include T supplements or DHEA. Several new progestins have been synthesized in the last decade. Dienogest is a hybrid progestin that is derived from both the pregnane and the estrane groups with a 17α‐cyanomethyl radical; drospirenone is derived from spirolactone. Somehow, the molecules available have demonstrated antiandrogenic properties. Cyproterone acetate (CPA) is the most potent antiandrogenic progestin, followed by dienogest, drosperinone, and chlormadinone acetate. Nomegestrol acetate and medrogestone also exert some antiandrogenic properties and are similar to chlormadinone acetate in antiandrogenic potency. While androgens act positively on libido in women, antiandrogenic properties in doses used in HRT do not appear to have a negative effect. Progestins used in HRT have varying pharmacological properties that are associated with different adverse effects. The new progestins with antiandrogenic properties avoid many of the androgenic side effects related to testosterone‐derived progestins. They also have the potential of not counteracting beneficial estrogen effects, for example, on the cardiovascular system or mental tone.


  • Maintenance of Dose Intensity in Adjuvant Chemotherapy of Breast Cancer in Patients Treated Outside a Clinical Trial - Results of a Retrospective Study

    by C. Jackisch, M. Jaber, U. Burkamp, A. Rody, S. Rösel, G. Raab, O. M. Koch, W. Dame, C. Gropp, L. Gleumes, et al.

    Die Qualität der adjuvanten Chemotherapie beim Mammakarzinom ist von genereller Bedeutung seit die Aufrechterhaltung der absoluten Dosis und der totalen Dosisintensität der verabreichten Chemotherapie das Überleben der Patientinnen beeinflusst. Diese retrospektive Analyse schließt 175 Patientinnen ein, die im Zeitraum von 1991 - 1999 an sechs Kliniken in Deutschland wegen eines primären Mammakarzinoms adjuvant systemisch behandelt wurden. Die Datenerhebung erfolgte anhand der Krankenblätter. Zur Auswertung kamen die Art der Behandlung, die jeweiligen im Chemotherapieregime enthaltenen Zytostatika, sowohl die geplanten als auch die tatsächlich verabreichten Dosierungen und der Zeitpunkt der Applikation. Ebenso wurden die hämatologischen und nicht hämatologischen Nebenwirkungen und das Ausmaß der supportiven Therapie erfasst. Im Beobachtungszeitraum kamen 18 verschiedene Chemotherapieregime zur Anwendung. Eine CMF-haltige Chemotherapie erhielten 110 Patientinnen (62 %), eine anthrazyklinhaltige Chemotherapie erhielten dagegen 65 Patientinnen (38 %). Von den 915 auszuwertenden Therapiezyklen wurden 870 Zyklen (95 %) effektiv verabreicht. Eine Therapieverschiebung von mehr als 7 Tagen erfolgte bei 100 Zyklen (11,5 %). Eine Dosisreduktion um mehr als 15 % erfolgte in 20 Fällen (2,3 %). Als relevanter Faktor für die Reduktion der relativen totalen Dosisintensität ergab sich der Zeitpunkt der Strahlentherapie, insbesondere wenn die Strahlentherapie vor oder während der Chemotherapie erfolgte (p = 0,05). Im Vergleich mit einer anthrazyklinhaltigen Chemotherapie ist eine CMF-haltige Chemotherapie mit einer größeren Anzahl von Dosiskompromissen bei der Behandlung außerhalb von klinischen Studien in der adjuvanten Situation verbunden (p = 0,02). Bei der Festlegung der interdisziplinären Therapieplanung von primären Mammakarzinomen ist ein besonderes Augenmerk auf die zeitliche Interaktion von Chemotherapie und Strahlentherapie zu legen. The quality of adjuvant chemotherapy is of general interest since maintenance of total dose and total dose intensity of chemotherapy delivered influences clinical outcome. This retrospective analysis evaluated 175 patients treated for primary breast cancer outside the setting of a clinical trial in six German centres from 1991 to 1999. The data retrieved from the patients' files were analysed for treatment types, drugs given per regimen with planned and delivered doses of the drugs, dates of dose delivery, haematological and non-haematological toxicities and amount and duration of supportive therapy. A total of 18 different schedules was recorded. 110 patients (62 %) received a CMF-type regime and 65 patients (38 %) an anthracycline-based protocol. Of the 915 total cycles 870 (95 %) were effectively administered. Of the delivered cycles 100 (11.5 %) were delayed by > 7 days and 20 (2.3 %) had dose reductions of > 15 %. An important influencing factor on relative total dose intensity was the concomitant radiation administered before or during chemotherapy (p = 0.05). CMF-type regimens were likely to have more dose delays compared to anthracycline-based regimens (p = 0.02) if used in the adjuvant setting. If chemotherapy is applied in combination with radiation special caution is mandatory to ensure maintenance of the delivered dose intensity.


  • Open Access

    International versions of the Menopause Rating Scale (MRS)

    by Lothar Aj Heinemann, Peter Potthoff, Hermann Pg Schneider

    Symptom scales for aging women have clinically been used for years and the interest in measuring health-related quality of life (HRQoL) has increased in recent years. The Menopause Rating Scale (MRS) is a formally validated scale according to the requirements for quality of life instruments. The aim of this paper is to review the current state of the instrument particularly concerning versions of the scale in different languages.


  • HRT and cancer risks

    by Hermann P.G Schneider


  • Weekly Dose-Dense Treatment with Taxanes in Metastatic Breast Cancer

    by A. Rody, C. Jackisch, E. Maier, A. Gärtner, J. Heinig, V. Coenen-Worch, A. Konieczny, H. Wiebringhaus, H. P. G. Schneider

    Weekly dose-dense cytotoxic treatment with taxanes is a promising option in the treatment of metastatic breast cancer. This retrospective analysis reflects our experiences in efficacy and toxicity using weekly administration of taxanes. In this setting 21 heavily pretreated patients with metastatic breast cancer received either paclitaxel (n = 11) at an initial dose of 70 - 100 mg/m2, or docetaxel (n = 10) at a dose of 35 mg/m2 intravenously. 110 infusions of docetaxel were administered in 10 patients (median 11 infusions/patient, range: 3 - 25). Overall response rate was 40 % and median response duration was 32 weeks (range 3 - 48 weeks). The worst non-hematologic toxicity was grade III alopecia. Hematologic toxicity occured in 28/110 cycles with grade I/II and 1/110 grade III leucopenia, in 17/110 cycles grade I/II and in 1/110 grade III thrombocytopenia; grade I/II anemia occured in 0/110 cycles and neurotoxicity grade I/II in 43/110 and grade III in 3/110 cycles. No grade IV toxicities were observed. In the second group 11 patients were treated with 126 infusions of paclitaxel (median 12 cycles/patient, range 6 - 25). The overall response rate was 55 %, median duration of response was 21 weeks (range 8 - 30 weeks). The main toxicity was grade I/II alopecia. In 21/126 cycles grade I/II and in 1/126 grade III leucopenia, no thrombocytopenia, 41/126 grade I/II and 1/126 grade IV anemia and 41/126 grade I/II neurotoxicity was recorded. Paclitaxel and docetaxel both are effective in the treatment of metastatic breast cancer with low toxicity and high efficacy resulting in a tolerable therapeutic index in heaviliy pretreated patients with metastatic breast cancer. Die dosisdichte wöchentliche Therapie mit Taxanen ist eine vielversprechende Option in der Therapie des metastasierten Mammakarzinoms. In dieser retrospektiven Analyse sollen Erfahrungen hinsichtlich Effektivität und Toxizität bei wöchentlicher Gabe von Taxanen beleuchtet werden. 21 erheblich vorbehandelte Patientinnen mit metastasiertem Mammakarzinom erhielten entweder Paclitaxel (n = 11) in einer Dosierung von 70 - 100 mg/m2 oder Docetaxel (n = 10) mit 35 mg/m2 intravenös. 110 Gaben Docetaxel konnten bei 10 Patienten appliziert werden (median 11 Zyklen/Patient, range 3 - 25). Die Gesamtansprechrate betrug 40 % und die mittlere Ansprechdauer 32 Wochen (range 3 - 48 Wochen). Die höchste nichthämatologische Toxizität war die Alopezie Grad III. In 28/110 Zyklen wurde eine hämatologische Grad I/II Toxizität und eine 1/110 eine Grad III Leukopenie beobachtet. 17/110 wiesen eine Thrombozytopenie Grad I/II und 1/110 Grad III auf. Grad I/II Anämie ereignete sich in 0/110 Zyklen und Neurotoxizität Grad I/II wurde in 43/110 und in 3/110 Zyklen mit Grad III beobachtet. Grad IV Toxizitäten lagen nicht vor. In der zweiten Gruppe wurden 11 Patienten mit 126 Zyklen Paxlitaxel behandelt (median: 12 Zyklen/Patient, range: 6 - 25). Die Gesamtansprechrate betrug hier 55 % und die mittlere Ansprechdauer 21 Wochen (range: 8 - 30 Wochen). Die Alopezie I/II war die am häufigsten eingetretene Toxizität. In 21/126 Zyklen wurde eine Grad I/II und in 1/126 Zyklen Grad III Leukopenie beobachtet, eine Thrombozytopenie trat nicht auf und eine Anämie Grad I/II zeigte sich in 41/126 Zyklen und 1/126 Grad IV. Eine Neurotoxizität Grad I/II wurde in 41/126 Zyklen dokumentiert. Somit sind Docetaxel und Paclitaxel in der Therapie des metastasierten Mammakarzinoms effiziente Substanzen, die mit einer tolerablen Toxizität bei guter Effektivität mit einem zufriedenstellenden therapeutischen Index, insbesondere in der stark vorbehandelten Patientengruppe, einhergehen.